Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

ConditionsCarcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Adenocarcinoma Digestive System Neoplasms Liver Neoplasms

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-80

SponsorShanghai Zhongshan Hospital

About this trial

This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.

Eligibility criteria

Qualifiers

Age 18-80 years, regardless of gender.

Clinically or pathologically confirmed HCC.

CNLC stage IIb-IIIa, deemed unresectable after multidisciplinary evaluation.

Having radiologically evaluable, untreated target lesions for ablation, with the largest diameter of the target tumor >5 cm.

Disqualifiers

Child-Pugh class C liver dysfunction.

Tumor thrombus in the main portal vein or hepatic vein.

Extensive metastatic disease with an expected survival <3 months.

Severe dysfunction of major organs (liver, kidney, heart, lung, or brain).

Trial design

Treatments tested in this trial

Multimodal Thermal Therapy

Treatment groups

17 Participants

are divided into 1 treatment group

Locations

Zhongshan Hospital, Fudan University200032, ShanghaiShanghai Municipality, China

Sponsors and collaborators

Shanghai Zhongshan Hospital

Lead sponsor

Source ClinicalTrials.gov